Another record year for Bayer – good progress with the acquisition of Monsanto

Group sales increase by 1.5 percent (Fx& portfolio adj. 3.5 percent) to EUR 46,769 million / Substantial sales and earnings increases at Pharmaceuticals / Consumer Health grows with competition / Crop Science successful in a difficult market environment / EBITDA before special items improves by 10.2 percent to EUR 11,302 million / Net income raised by 10.2 percent to EUR 4,531 million / Core earnings per share increase by 7.3 percent to EUR 7.32 / Operating cash flow climbs by 20.8 percent to EUR 8,259 million / Forecast for 2017: further growth in sales and earnings
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news